OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC

June 13th 2025

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Dr Fathi on the Efficacy and Safety of Ziftomenib in R/R NPM1-Mutant AML

June 13th 2025

Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.

Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS

June 13th 2025

Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.

Dr Dahiya on the Safety Profile of KITE-363 in Relapsed/Refractory B-Cell Lymphoma

June 13th 2025

Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.

Dr Graham on Advancements in the Management of Ovarian Cancer

June 13th 2025

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.

Dr Adkins on the FDA Approval of Pembrolizumab for Neoadjuvant/Adjuvant Treatment in Resectable, Locally Advanced HNSCC

June 12th 2025

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

Dr Sonpavde on Nivolumab Plus Ipilimumab in Untreated Unresectable/Metastatic Urothelial Carcinoma

June 12th 2025

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Dr Jankowski on the Telomere-Targeted Agent THIO With Cemiplimab in Advanced NSCLC

June 12th 2025

Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.

Dr Benjamin on Using Real-World Data to Bridge Knowledge Gaps in Urothelial Cancer Care

June 12th 2025

David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.

Dr Hayne on Mitomycin/BCG as an Alternative to BCG Alone in Non–Muscle-Invasive Bladder Cancer

June 12th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.

Dr Huang on the FDA Approval of Mitomycin Intravesical Solution for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

June 12th 2025

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

Dr Gutierrez on Dato-DXd Plus Rilvegostomig in Advanced/Metastatic NSCLC

June 11th 2025

Martin E. Gutierrez, MD, discusses data for Dato-DXd plus rilvegostomig in advanced or metastatic NSCLC.

Dr Daver on the Efficacy of Revumenib in NPM1+ Relapsed/Refractory AML

June 11th 2025

Naval G. Daver, MD, highlights the efficacy of revumenib for the treatment of patients with NPM1-mutant relapsed/refractory acute myeloid leukemia.

Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC

June 11th 2025

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Dr Pennell on the Significance of the FDA Approval of Taletrectinib for ROS1+ NSCLC

June 11th 2025

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Dr Sabari on c-MET as a Potential Biomarker of Response in EGFR Wild-Type NSCLC

June 11th 2025

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

Dr Zhang on Sacituzumab Tirumotecan in Pretreated Advanced EGFR-Mutated NSCLC

June 11th 2025

Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.

Dr Kalinsky on Evolving Roles for the CLEOPATRA and DESTINY-Breast09 Regimens in HER2+ Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

Dr Cristofanilli on the Potential Role of Serial ESR1 Mutation Monitoring in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Massimo Cristofanilli, MD, details the implications of serial ESR1 mutation monitoring using ctDNA in HR-positive/HER2-negative advanced breast cancer.